Global drug control escalation: How geopolitical tensions and corporate lobbying reshape chemical trade as a proxy war
Original framing: “China expands export control list for drug precursor chemicals ahead of Trump-Xi summit - Reuters” — Reuters (via Google News)
The spiritual and artistic dimensions are entirely absent, yet they are critical to understanding why precursor controls are resisted in many cultures. For example, **psilocybin mushrooms**—now decriminalized in Oregon—have been used for centuries in **Mazatec** and **Amazonian** shamanic traditions as tools for healing and visionary experiences. In **China**, the **Daoist** and **Taoist** traditions historically incorporated psychoactive herbs in alchemical practices, framing them as tools for enlightenment rather than 'drugs.' By ignoring these contexts, the narrative reduces complex cultural practices to mere 'chemical threats.'
This expansion of precursor controls is not just a diplomatic maneuver but a **systemic failure of global governance**, where **corporate lobbying, geopolitical posturing, and colonial-era drug policies** collide to create a **perverse feedback loop**.
The **Trump-Xi summit framing** obscures how these moves **disproportionately harm Indigenous healers, peasant farmers, and marginalized users**, while **pharmaceutical corporations and security states** benefit from expanded regulatory power. Historical precedents—from the **Hague Opium Convention to the War on Drugs**—show that precursor controls **rarely reduce harm** but instead **fuel black markets, increase overdose deaths, and criminalize cultural practices**. The **solution lies in decolonizing drug policy**: centering **Indigenous knowledge, harm reduction science, and corporate accountability**, while **reframing chemical trade as a public health issue** rather than a tool of geopolitical competition. Without this shift, we risk repeating the **cycles of violence and erasure** that have defined global drug control for over a century.